Corpus overview


MeSH Disease

Human Phenotype


gender (1)


antibody (1)

    displaying 1 - 2 records in total 2
    records per page

    A Case Report of Heparin-Induced Thrombocytopenia HP Thrombocytopenia MESHD in a Patient One Month after Coronary Artery Bypass Graft Surgery in the Era of Coronavirus Disease MESHD 2019

    Authors: ibrahim mungan; seval izdeş

    doi:10.21203/ Date: 2020-06-12 Source: ResearchSquare

    Background : Coronavirus infectious disease MESHD 2019 (COVID-19), which evolved to a global pandemic issue leads to coagulation system abnormalities and low molecular heparin or unfractionated heparin is advised. Heparin-induced thrombocytopenia HP thrombocytopenia MESHD (HIT) is one of the most worried complications of heparin exposure.Case Presentation: In this case report, we presented a 75 year- old male TRANS patient with suspicious COVID-19 infection MESHD who admitted to our intensive care unit one month after cardiac surgery. On admission due to increased D-dimer level and history of CABG, he was started to LMWH (enoxaparin) 0.5 mg/kg twice daily yet HIT occurred and enoxaparin was held. Fondaparinux was started to decrease the thrombosis MESHD risk.Conclusion: In the era of COVID-19, the management of coagulopathy is important while HIT should be mind in every patient after the preliminary heparin treatment.

    Heparin-induced thrombocytopenia HP thrombocytopenia MESHD is associated with a high risk of mortality in critical COVID-19 patients receiving heparin-involved treatment

    Authors: Xuan Liu; Xiaopeng Zhang; Yongjiu Xiao; Ting Gao; Guangfei Wang; Zhongyi Wang; Zhang Zhang; Yong Hu; Qincai Dong; Songtao Zhao; Li Yu; Shuwei Zhang; Hongzhen Li; Kaitong Li; Wei Chen; Xiuwu Bian; Qing Mao; Cheng Cao

    doi:10.1101/2020.04.23.20076851 Date: 2020-04-28 Source: medRxiv

    Background Coronavirus infectious disease MESHD 2019 (COVID-19) has developed into a global pandemic. It is essential to investigate the clinical characteristics of COVID-19 and uncover potential risk factors for severe disease MESHD to reduce the overall mortality rate of COVID-19. Methods Sixty-one critical COVID-19 patients admitted to the intensive care unit (ICU) and 93 severe non-ICU patients at Huoshenshan Hospital (Wuhan, China) were included in this study. Medical records, including demographic, platelet counts, heparin-involved treatments, heparin-induced thrombocytopenia HP thrombocytopenia MESHD-(HIT) related laboratory tests, and fatal outcomes of COVID-19 patients were analyzed and compared between survivors and nonsurvivors. Findings Sixty-one critical COVID-19 patients treated in ICU included 15 survivors and 46 nonsurvivors. Forty-one percent of them (25/61) had severe thrombocytopenia MESHD thrombocytopenia HP, with a platelet count (PLT) less than 50x109/L, of whom 76% (19/25) had a platelet decrease of >50% compared to baseline; 96% of these patients (24/25) had a fatal outcome. Among the 46 nonsurvivors, 52.2% (24/46) had severe thrombocytopenia MESHD thrombocytopenia HP, compared to 6.7% (1/15) among survivors. Moreover, continuous renal replacement therapy (CRRT) could induce a significant decrease in PLT in 81.3% of critical CRRT patients (13/16), resulting in a fatal outcome. In addition, a high level of anti-heparin-PF4 antibodies SERO, a marker of HIT, was observed in most ICU patients. Surprisingly, HIT occurred not only in patients with heparin exposure, such as CRRT, but also in heparin-naive patients, suggesting that spontaneous HIT may occur in COVID-19. Interpretation Anti-heparin-PF4 antibodies SERO are induced in critical COVID-19 patients, resulting in a progressive platelet decrease. Exposure to a high dose of heparin may trigger further severe thrombocytopenia MESHD thrombocytopenia HP with a fatal outcome. An alternative anticoagulant other than heparin should be used to treat COVID-19 patients in critical condition.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).



MeSH Disease
Human Phenotype

Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.